Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Key Points
Key Points
- Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
- Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
- Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.
Treatment
...eatment...
...t Astrocytic and Oligodendroglial T...
...odendroglioma, IDH-mutant, 1p/19q co-...
Recommendation 1.1People with oligodendroglio...
...emozolomide is a reasonable altern...
Recommendation 1.2Within the group...
...oma, IDH-mutant, 1p/19q co-deleted...
...ion 1.3People with oligodendroglioma...
...a reasonable alternative to PCV when toxicity is...
...IDH-mutant, 1p/19q non-codeleted, CNS WHO gra...
...on 1.4People with astrocytoma, IDH-mutan...
...dation 1.5In astrocytoma, IDH-mutant, 1p/19...
...toma, IDH-mutant, 1p/19q non-codeleted...
....6People with astrocytoma, IDH-mutant, 1p/1...
..., IDH-mutant, CNS WHO grade 4 (former I...
...ation 1.7People with astrocytoma, IDH-mutant CN...
...stoma and Other IDH-wildtype Diffuse...
...endation 2.1People with astrocytomas, IDH-wildtype...
...n 2.2Concurrent temozolomide and ra...
...dation 2.3Six months of adjuvant temozolomide s...
...ation 2.4Alternating electric field therapy may...
...mmendation 2.5Bevacizumab is NOT recommende...
...ation 2.6In people with glioblastoma, IDH-wildtype...
...2.7In people with glioblastoma, IDH-wildtype...
...n 2.8No recommendation for or against any thera...
...with recurrent glioblastoma should be referred fo...
...ommendation 2.9No recommendation for or agai...
...fuse midline glioma should be referred for par...
Table 1. Reasonable Doses and Schedules by Recommendation
...Reasonable Doses and Schedules by Recom...